Advertisement

Topics

Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape

17:35 EST 14 Feb 2018 | SCRIP

The multibillion-dollar collaboration includes 20 studies, including two pivotal trials in renal cell carcinoma and non-small cell lung cancer that...

      

Related Stories

 

Original Article: Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape

NEXT ARTICLE

More From BioPortfolio on "Nektar/Bristol Deal May Shake Up Immuno-Oncology Landscape"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Mergers & Acquisitions
Commercial and market reports on mergers and acquisitions in the biotechnology, pharmaceutical, medical device and life-science industries. Mergers and acquisitions (abbreviated M&A;) is an aspect of corporate strategy, corporate finance and manageme...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...